Mar 07, 2025 9:25 am EST Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Mar 04, 2025 7:00 am EST Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Jan 02, 2025 9:15 am EST Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy